| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1100 | 2018 |
| Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma C Tognon, SR Knezevich, D Huntsman, CD Roskelley, N Melnyk, ... Cancer cell 2 (5), 367-376, 2002 | 994 | 2002 |
| Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML JE Maxson, J Gotlib, DA Pollyea, AG Fleischman, A Agarwal, CA Eide, ... New England Journal of Medicine 368 (19), 1781-1790, 2013 | 620 | 2013 |
| Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition V Evdokimova, C Tognon, T Ng, P Ruzanov, N Melnyk, D Fink, A Sorokin, ... Cancer cell 15 (5), 402-415, 2009 | 549 | 2009 |
| Integrated proteogenomic characterization of clear cell renal cell carcinoma DJ Clark, SM Dhanasekaran, F Petralia, J Pan, X Song, Y Hu, ... Cell 179 (4), 964-983. e31, 2019 | 482 | 2019 |
| The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation G Leprivier, M Remke, B Rotblat, A Dubuc, ARF Mateo, M Kool, ... Cell 153 (5), 1064-1079, 2013 | 439 | 2013 |
| Proteogenomic and metabolomic characterization of human glioblastoma LB Wang, A Karpova, MA Gritsenko, JE Kyle, S Cao, Y Li, D Rykunov, ... Cancer cell 39 (4), 509-528. e20, 2021 | 428 | 2021 |
| Proteogenomic characterization of endometrial carcinoma Y Dou, EA Kawaler, DC Zhou, MA Gritsenko, C Huang, L Blumenberg, ... Cell 180 (4), 729-748. e26, 2020 | 348 | 2020 |
| Translational activation of HIF1α by YB-1 promotes sarcoma metastasis AM El-Naggar, CJ Veinotte, H Cheng, TGP Grunewald, GL Negri, ... Cancer cell 27 (5), 682-697, 2015 | 324 | 2015 |
| Regulation of RasGRP via a phorbol ester-responsive C1 domain CE Tognon, HE Kirk, LA Passmore, IP Whitehead, CJ Der, RJ Kay Molecular and cellular biology, 1998 | 303 | 1998 |
| The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ... Cancer discovery 9 (7), 910-925, 2019 | 271 | 2019 |
| Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma C Huang, L Chen, SR Savage, RV Eguez, Y Dou, Y Li, ... Cancer cell 39 (3), 361-379. e16, 2021 | 236 | 2021 |
| Expression Cloning of lfc, a Novel Oncogene with Structural Similarities to Guanine Nucleotide Exchange Factors and to the Regulatory Region of Protein Kinase C (∗) I Whitehead, H Kirk, C Tognon, G Trigo-Gonzalez, R Kay Journal of Biological Chemistry 270 (31), 18388-18395, 1995 | 192 | 1995 |
| IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors V Evdokimova, CE Tognon, T Benatar, W Yang, K Krutikov, M Pollak, ... Science signaling 5 (255), ra92-ra92, 2012 | 177 | 2012 |
| Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants CA Eide, MS Zabriskie, SLS Stevens, O Antelope, NA Vellore, H Than, ... Cancer Cell 36 (4), 431-443. e5, 2019 | 175 | 2019 |
| An expanded universe of cancer targets WC Hahn, JS Bader, TP Braun, A Califano, PA Clemons, BJ Druker, ... Cell 184 (5), 1142-1155, 2021 | 159 | 2021 |
| Reduced proliferation and enhanced migration: two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1 V Evdokimova, C Tognon, T Ng, PHB Sorensen Cell cycle 8 (18), 2901-2906, 2009 | 156 | 2009 |
| ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex Z Li, CE Tognon, FJ Godinho, L Yasaitis, H Hock, JI Herschkowitz, ... Cancer cell 12 (6), 542-558, 2007 | 156 | 2007 |
| Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins MA Davare, A Saborowski, CA Eide, C Tognon, RL Smith, J Elferich, ... Proceedings of the National Academy of Sciences 110 (48), 19519-19524, 2013 | 152 | 2013 |
| The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation C Tognon, M Garnett, E Kenward, R Kay, K Morrison, PHB Sorensen Cancer research 61 (24), 8909-8916, 2001 | 152 | 2001 |
